Business
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nTopline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022\n\n\n\nZetomipzomib assigned as nonproprietary name for lead candidate, KZR-616\n\n\n\nCash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.\n\n“In 2021, we made significant progress in each of our programs, achieving target enrollment in both of our Phase 2 trials with zetomipzomib, sharing positive interim results from our MISSION Phase 2 study, and launching a Phase 1 trial in solid tumors with our novel protein secretion inhibitor, KZR-261,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer. “We look forward to continued momentum across the company in 2022, including the presentation of topline results from the MISSION and PRESIDIO trials in the second quarter and preparing for the exciting next phase of development with our first-in-class immunoproteasome inhibitor, zetomipzomib.”\n\nZetomipzomib Assigned as Nonproprietary Name for KZR-616\n\nThe International Nonproprietary Name (INN) of zetomipzomib has been selected as the proposed nonproprietary name for KZR-616. The established suffix “-ipzomib” is being utilized to convey the compound’s mode of action to selectively inhibit the immunoproteasome.\n\nKZR-616: Selective Immunoproteasome Inhibitor\n\nMISSION – Phase 2 clinical trial of KZR-616 in patients with lupus nephritis (LN) (NCT03393013)\n\n\nIn November 2021, Kezar presented positive interim results from the MISSION Phase 2 clinical trial of KZR-616, in which five patients had reached the end of treatment, and ten patients had reached week 13 of treatment. The interim results showed a clinically meaningful renal response at the end of treatment for this subset of patients. Four of five patients who completed treatment at week 25 with KZR-616 demonstrated clinically meaningful reduction in proteinuria to less than 0.8 urine protein to creatine ratio (UPCR). Clinically meaningful reductions in UPCR were also observed in five of ten p...